Evidence map›Paper›PMID 29168253›Full record

Trial reportTransfusion2018

Genomewide association study of HLA alloimmunization in previously pregnant blood donors.

Mark Seielstad, Grier P Page, Nathan Gaddis, Marion Lanteri, Tzong-Hae Lee, Ram Kakaiya, Lisa F Barcellos, Lindsey A Criswell, Darrell Triulzi, Philip J Norris and 2 more

Abstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Transfusion, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mark SeielstadBlood Systems Research Institute, University of California San Francisco, San Francisco, California.
Grier P PageRTI, Atlanta, Georgia.
Nathan GaddisRTI, Atlanta, Georgia.
Marion LanteriBlood Systems Research Institute, University of California San Francisco, San Francisco, California.
Tzong-Hae LeeBlood Systems Research Institute, University of California San Francisco, San Francisco, California.
Ram KakaiyaLifesource, Rosemont, Illinois.
Lisa F BarcellosDivision of Epidemiology, School of Public Health, University of California Berkeley, Berkeley, California.
Lindsey A CriswellRosalind Russell/Ephraim P. Engleman Rheumatology Research Center, Department of Medicine, University of California San Francisco, San Francisco, California.
Darrell TriulziDepartment of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Philip J NorrisBlood Systems Research Institute, University of California San Francisco, San Francisco, California.ORCID 0000-0003-0526-2088
Michael P BuschBlood Systems Research Institute, University of California San Francisco, San Francisco, California.
NHLBI REDS-III Study Investigators

Funding

Validating the link between NXPH2 and alloimmunizationR21HL124260 · NHLBI · VITALANT · PI NORRIS, PHILIP J. · 2015 to 2016
$435k
NHLBI NIH HHS HHSN268201100001INHLBI NIH HHS HHSN268201100002INHLBI NIH HHS HHSN268201100003INHLBI NIH HHS HHSN268201100004INHLBI NIH HHS HHSN268201100005CNHLBI NIH HHS HHSN268201100005GNHLBI NIH HHS HHSN268201100005INHLBI NIH HHS HHSN268201100006CNHLBI NIH HHS R21 HL124260WHI NIH HHS HHSN268201100001CWHI NIH HHS HHSN268201100002CWHI NIH HHS HHSN268201100003CWHI NIH HHS HHSN268201100004C
6 · The paper itself

Abstract

backgroundAlloimmunization through blood transfusion, transplantation, or circulating fetal cells during pregnancy is a significant concern. Some exposed individuals make alloantibodies while others do not, implying variation in genetic risk factors. STUDY DESIGN AND

methodsWe conducted a genomewide association study (GWAS) of 9,427,497 single-nucleotide polymorphisms (SNPs) to identify genetic variants for HLA alloimmunization in previously pregnant blood donors with (n = 752) and without (n = 753) HLA Class I or II alloantibodies.

resultsA SNP in the neurexophilin 2 (NXPH2) gene surpassed genome-wide significance (p = 2.06 × 10

conclusionFurther work to extend the GWAS approach and to characterize variants in NXPH2 and E2F7 in the context of alloantibody formation is warranted.

Indexed as

Blood DonorsGenome-Wide Association StudyPolymorphism, Single NucleotideAdultE2F7 Transcription FactorFemaleFetomaternal TransfusionGlycoproteinsHumansIsoantibodiesNeuropeptidesPregnancyE2F7 protein, humanE2F7 Transcription FactorGlycoproteinsIsoantibodiesneurexophilinNeuropeptides

Identifiers

PMID29168253
PMCPMC5803399

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.